Nurix Therapeutics Inc (NAS:NRIX)
$ 15.41 -0.49 (-3.08%) Market Cap: 940.44 Mil Enterprise Value: 756.14 Mil PE Ratio: 0 PB Ratio: 4.49 GF Score: 67/100

Nurix Therapeutics Inc at Wells Fargo Targeted Protein Degradation Summit (Virtual) Transcript

Feb 21, 2023 / 01:00PM GMT
Release Date Price: $9.03 (-7.10%)
Derek Archila
Wells Fargo - Analyst

Hey, good morning, everyone, and thanks for joining our first annual TPD summit. We view TPD as a very fascinating and broadly applicable modality that continues to evolve at a very rapid pace. So, we published our updated white paper last week and our discussions today with industry leaders look to dive a little bit deeper on some of those hot topics of the day.

So, our first panel this morning, we'll be discussing overcoming resistance with targeted protein degradation. And I'm going to turn it over to a man who needs no introduction. My colleague, Jim Birchenough who will be hosting this panel. So, Jim, please take it away.

Jim Birchenough
Wells Fargo - Analyst

Thanks, Derek. Really appreciate all the work you've done in the TPD space and for setting up this summit. We've got a terrific panel for this first topic, as Derek suggested, overcoming resistance with targeted protein degradation. We have with us this morning, Arthur Sands, who's the CEO of Nurix since 2014. Most of you will know, Arthur, as the co

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot